Navigation Links
How do we kill rogue cells?
Date:10/31/2010

A team of Melbourne and London researchers have shown how a protein called perforin punches holes in, and kills, rogue cells in our bodies. Their discovery of the mechanism of this assassin is published today in the science journal Nature.

"Perforin is our body's weapon of cleansing and death," says project leader Prof James Whisstock from Monash University.

"It breaks into cells that have been hijacked by viruses or turned into cancer cells and allows toxic enzymes in, to destroy the cell from within. Without it our immune system can't destroy these cells. Now we know how it works, we can start to fine tune it to fight cancer, malaria and diabetes," he says.

The first observations that the human immune system could punch holes in target cells was made by the Nobel laureate Jules Bordet over 110 years ago. But how?

Researchers from Monash University and the Peter MacCallum Cancer Centre in Melbourne, and Birkbeck College in London collaborated on the ten-year study to unravel the molecular structure and function of perforinthe protein responsible. The structure was revealed with the help of the Australian Synchrotron, and with powerful electron microscopes at Birkbeck. Combining the detailed structure of a single perforin molecule with the electron microscopy reconstruction of a ring of perforins forming a hole in a model membrane reveals how this protein assembles to punch holes in cell membranes.

The new research has confirmed that the important parts of the perforin molecule are quite similar to those in toxins deployed by bacteria such as anthrax, listeria and streptococcus. "The molecular structure has survived for close to two billion years, we think," says Prof Joe Trapani, head of the Cancer Immunology Program at Peter Mac.

"This work is a dramatic illustration of the importance of the synchrotron," says Whisstock. "We simply couldn't have done it without this wonderful facility."

The weapon of death is a powerful molecule. If perforin isn't working properly the body can't fight infected cells. And there is evidence from mouse studies, says Trapani, that defective perforin leads to an upsurge in malignancy, particularly leukaemia.

Perforin is also the culprit when the wrong cells are marked for elimination, either in autoimmune disease conditions, such as early onset diabetes, or in tissue rejection following bone marrow transplantation.

So the researchers are now investigating ways to boost perforin for more effective cancer protection and therapy for acute diseases such as cerebral malaria. And with the help of a $1 million grant from the Wellcome Trust they are working on potential inhibitors to suppress perforin and counter tissue rejection.


'/>"/>

Contact: Niall Byrne
niall@scienceinpublic.com.au
61-417-131-977
Science in Public
Source:Eurekalert

Related biology news :

1. Oregons Rogue River Basin to face climate-change hurdles
2. iGEM team helps prevent rogue use of synthetic biology
3. Does the existing standard of care supply energy sources to brain tumor cells?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... , February 28, 2017 News solutions for ... ... from 14 to 16 March, Materna will present ... show how seamless travel is a real benefit for passengers. ... biometrics to their passenger touch point solutions to take passengers through ...
(Date:2/26/2017)... , Feb. 25, 2017  Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... Recidivism and Reentry. "Too often, too ... prisons and county jails are trying to tackle ... inmates and friends and family members. While significant steps ...
(Date:2/21/2017)... and PORTLAND, Ore. , ... and the Avamere Family of Companies (Avamere Health Services, ... announced a six-month research study that will apply the ... eldercare at senior living and health centers. By analyzing ... hopes to gain insights into physical and environmental conditions, ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... Denmark , March 22, 2017  Ascendis ... utilizes its innovative TransCon technology to address significant ... financial results for the full year ended December ... significant year for our company as we broadened ... a leading, integrated rare disease company with an ...
(Date:3/22/2017)... --  iSpecimen ®, the marketplace for human ... (DPS), a full-service anatomic pathology reference lab serving ... , has joined a program offered by iSpecimen ... to make human biospecimens and associated data available to ... in 2015 as a collaboration between iSpecimen and DHIN, ...
(Date:3/22/2017)... 2017   Boston Biomedical , an industry leader ... target cancer stemness pathways, today announced its Board of ... Chief Executive Officer, effective April 24, 2017. ... , M.D., FACP, who has led Boston Biomedical since ... leadership, Boston Biomedical has grown from a "garage startup" ...
(Date:3/22/2017)... , ... March 21, 2017 , ... ... biologics. To acquire information on the desired increase and/or decrease in antibody-dependent cellular ... for rapid N-glycosylation profiling of therapeutic antibodies. , To meet this demand, ...
Breaking Biology Technology: